New Multiple Sclerosis Phenotypic Classification
European Neurology · 2014 · 4,301 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
LUBLIN, F. D. (2014). New multiple sclerosis phenotypic classification. European Neurology, 72(Suppl. 1), 1–5. https://doi.org/10.1159/000367614
In text: (LUBLIN, 2014)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: In 1996, the clinical course of multiple sclerosis (MS) was characterized as relapsing-remitting, primary progressive, secondary progressive or progressive relapsing. Since then, an increased understanding of MS and its pathology prompted a re-examination of these clinical phenotypes. Main recommendations of the 2013 revisions are provided herein. SUMMARY: Clinically isolated syndrome has been added, and progressive relapsing MS has been eliminated, from the clinical course descriptions. All forms of MS should be further subcategorized as either active or non-active. Active MS is defined as the occurrence of clinical relapse or the presence of new T2 or gadolinium-enhancing lesions over a specified period of time, preferably at least one year. An additional subcategory for patients with progressive MS differentiates between those who have shown signs of disability progression over a given time period and those who have remained stable. The term 'worsening' is recommended to describe patients whose disease is advancing for any reason, whereas 'disease progression' should be reserved for those with progressive disease who are truly progressing (as opposed to worsening from a relapse). The term 'benign' should be used with caution as the course of MS can worsen at any time, even after many years of apparent stability. Key Messages: Newer characterizations of MS phenotypes include a consideration of disease activity (based on the clinical relapse rate and imaging findings) and disease progression. Accurate clinical course descriptions are useful for communication, prognostication, clinical trial design and to guide everyday clinical decision-making.
Related papers
- Rating neurologic impairment in multiple sclerosis1983
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria2011
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis2001
- The Fatigue Severity Scale1989
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”2005
Metadata from OpenAlex (CC0). Citations are generated from the published record.